Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
860
Frequently Asked Questions
What is Market Cap of Intra-Cellular Therapies Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Intra-Cellular Therapies Inc market cap is $14.05B.
What is the 52-week high for Intra-Cellular Therapies Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Intra-Cellular Therapies Inc 52 week high is $131.98 as of September 10, 2025.
What is the 52-week low for Intra-Cellular Therapies Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Intra-Cellular Therapies Inc 52 week low is $64.09 as of September 10, 2025.
What is Intra-Cellular Therapies Inc stock price today?
Intra-Cellular Therapies Inc stock price today is $131.87.
What was Intra-Cellular Therapies Inc stock price yesterday?
Intra-Cellular Therapies Inc stock price yesterday was $131.92.
What is the PE ratio of Intra-Cellular Therapies Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Intra-Cellular Therapies Inc’s P/E ratio is -182.70.
What is the Price-to-Book ratio of Intra-Cellular Therapies Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Intra-Cellular Therapies Inc P/B ratio is 12.1988.
What is the 50-day moving average of Intra-Cellular Therapies Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Intra-Cellular Therapies Inc 50-day moving average is $130.09.
How many employess does Intra-Cellular Therapies Inc has?